FDA Advisory Committee Sets Review Date for Remestemcel-L
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- S&P DJI Announces June 2020 Quarterly Rebalance
- Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
- MSB Completes Financing For Covid-19 ARDS Manufacturing
- Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
- 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Later from Mesoblast
- COVID-19/GVHD Update, Quarterly Report and Appendix 4C
- Update on Scheduled FDA Advisory Committee Meeting
- ODAC Votes in Favor of Remestemcel-L for GvHD
- DSMB Recommends Continuation of Phase 3 COVID-19 Trial
- MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast